- Report
- December 2022
- 123 Pages
Asia Pacific
From €1385EUR$1,500USD£1,159GBP
- Report
- December 2022
- 106 Pages
North America
From €1385EUR$1,500USD£1,159GBP
- Report
- April 2025
- 132 Pages
Global
From €4480EUR$4,850USD£3,747GBP
- Report
- March 2024
- 132 Pages
Global
From €4295EUR$4,650USD£3,592GBP
- Report
- October 2024
- 96 Pages
Global
From €3500EUR$4,059USD£3,030GBP
- Report
- July 2023
- 84 Pages
Global
From €3500EUR$4,059USD£3,030GBP
- Report
- May 2022
- 78 Pages
Global
From €3500EUR$4,059USD£3,030GBP
Gastroesophageal Reflux Disease (GERD) is a chronic digestive disorder that affects the lower esophageal sphincter (LES), the ring of muscle between the esophagus and stomach. GERD is a common disorder, and is often treated with medications that reduce the amount of acid produced in the stomach. These medications are part of the Gastrointestinal Drugs market.
Gastrointestinal Drugs are used to treat a variety of digestive disorders, including GERD. These drugs can be divided into two categories: antacids and proton pump inhibitors (PPIs). Antacids are used to neutralize stomach acid, while PPIs are used to reduce the amount of acid produced in the stomach. Both types of drugs are available in both prescription and over-the-counter forms.
The Gastroesophageal Reflux Disease Drug market is a subset of the Gastrointestinal Drugs market. This market includes both prescription and over-the-counter medications used to treat GERD. Some of the major companies in this market include AstraZeneca, GlaxoSmithKline, Pfizer, Merck, and Takeda. Show Less Read more